Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B
Hepatitis B infection has a complex natural history and causes a wide spectrum of disease. Although effective vaccines are available, universal vaccination has yet not been reached. Currently, an estimated 350 million people are chronically infected, and 0.5-1.2 million subjects die every year due to long-term sequalae of hepatitis B related chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma Despite evidence-based treatment guidelines areas of disagreement on the management of chronic hepatitis B virus (HBV) infection still exist. With the currently approved treatment options the ultimate goal is to prevent the development of long-term sequelae of chronic liver disease. Current treatment strategies consist of either therapies with fi nite duration that aims to achieve sustained off-treatment remission (interferon-based therapy), or long-term therapy that aims to maintain on-treatment response (nucleos(t)ide analogues).
|Publisher||Erasmus MC: University Medical Center Rotterdam|
|Promotor||Janssen, H.L.A. (Harry)|
|Sponsor||Erasmus MC Rotterdam, Nederlandse Vereniging voor Gastroenterologie, Novartis, Gilead Sciences, Bristol-Myers Squibb, J.E. Jurriaanse Stichting|
|Keywords||HIV, Hepatitis B, infectious diseases, liver diseases, virology|
Reijnders, J.G.P.. (2010, November 24). Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B. Erasmus MC: University Medical Center Rotterdam. Retrieved from http://hdl.handle.net/1765/21420